Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review and Practice Guideline
Clinical Oncology, 07/17/2012
Petrella T et al. – The updated literature review indicates that adjuvant interferon therapy does not confer a significant long–term overall survival benefit in patients with high–risk resected primary melanoma; however, a significant disease–free survival (DFS) benefit for high–dose interferon or pegylated interferon treatment has been shown. An revised practice guideline was developed based on the systematic review.